Viking Therapeutics Nears Phase III Trials Despite Financial Struggles
PILLAR DIAGNOSTIC // WEEK 12
“Regulatory label restrictions cap Orforglipron’s addressable market to non-fatty liver/hepatitis patients despite bullish machine forecasts, while institutions are front-running the maintenance study catalyst before the market fully discounts this growth ceiling.”
Proposed action
Avoid chasing new highs; consider hedging or trimming long exposure.
THE MECHANICS
Tape & flow
Maintenance study acts as a major near-term catalyst poised to accelerate flows, while ACT Capital’s $7.25 million stake equates to 206,100 shares of VKTX, injecting fresh institutional demand.
THE MACHINE
Operational momentum
Amylin expects Phase I SAD data by year-end as a second catalyst beyond its Maintenance Study, while Viking is advancing its VK2735 obesity candidate—injectable Phase III ongoing and oral Phase III set for Q3 2026—against a backdrop of demand that outstripped supply, implying ample opportunity to capture market share upon approval.
THE MAP
Structure & constraints
Orfoglipron is advancing in phase 3 with both injectable and oral formulations under regulatory constraints that restrict approval to patients without fatty liver or hepatitis.
THE MOOD
Consensus & positioning
Optimism around Viking’s oral pill matching injectable profiles and strong phase results—with 16%+ weight loss and no plateau—has fueled a bullish narrative, spurring expectations of partnerships and stock upside; however, persistent losses, a neutral hold rating, and looming EPS decline inject caution.